Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 5/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 5/20 | 0.50 |
| ▸ | PRSS2 | P07478 | 5/20 | 0.50 |
| ▸ | PRSS3 | P35030 | 5/20 | 0.50 |
| ▸ | CA12 | O43570 | 6/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.36 |
| ▸ | CA1 | P00915 | 7/20 | 0.33 |
| ▸ | CA2 | P00918 | 6/20 | 0.33 |
| ▸ | CA7 | P43166 | 2/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 2/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2339824 | 1.00 | F2 (0.50) | F2PRSS1PRSS2PRSS3CA12 | |
| SCHEMBL446590 | 0.83 | F2 (0.44) | F2PRSS1PRSS2PRSS3CA12 | |
| SCHEMBL2615565 | 0.82 | F2 (0.43) | F2PRSS1PRSS2PRSS3CA12 | |
| SCHEMBL15893686 | 0.82 | F2 (0.43) | F2PRSS1PRSS2PRSS3CA12 | |
| SCHEMBL2369612 | 0.78 | F2 (0.40) | F2PRSS1PRSS2PRSS3CA12 | |
| SCHEMBL2369616 | 0.78 | F2 (0.40) | F2PRSS1PRSS2PRSS3CA12 | |
| SCHEMBL16298358 | 0.78 | F2 (0.40) | F2PRSS1PRSS2PRSS3CA12 | |
| SCHEMBL14493144 | 0.77 | F2 (0.39) | F2PRSS1PRSS2PRSS3CA12 | |
| SCHEMBL7370215 | 0.76 | F2 (0.56) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL29539627 | 0.75 | F2 (0.44) | F2PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115260193-A | Compounds and methods for treating rabies | 株式会社大分大学先端医学研究所 | 2022-11-01 | — | — | CN | disclosed |
| CN-115052661-A | Compound and drug using the same | 株式会社大分大学先端医学研究所 | 2022-09-13 | — | — | CN | disclosed |
| CN-112839944-B | Compounds and methods for treating rabies | 株式会社大分大学先端医学研究所 | 2022-08-05 | — | — | CN | disclosed |
| US-11135234-B2 | Effective aminoglycoside antibiotic for multidrug-resistant bacteria | MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) | 2021-10-05 | — | — | US | disclosed |
| WO-2021161511-A1 | COMPOUND AND DRUG CONTAINING SAME | 株式会社大分大学先端医学研究所 | 2021-08-19 | — | — | WO | disclosed |
| CN-113195463-A | Novel chemiluminescent substrates for factor Xa | 恩泽尔私人有限公司 | 2021-07-30 | — | — | CN | disclosed |
| CN-112839944-A | Compounds and methods for treating rabies | 株式会社大分大学先端医学研究所 | 2021-05-25 | — | — | CN | disclosed |
| CN-108026133-B | Novel aminoglycoside antibiotics effective against multidrug resistant bacteria | 公益财团法人微生物化学研究会 | 2021-05-07 | — | — | CN | disclosed |
| CN-108254231-B | Method for preparing sample for analysis and analysis method | 株式会社岛津制作所 | 2021-02-26 | — | — | CN | disclosed |
| US-20200155582-A1 | EFFECTIVE AMINOGLYCOSIDE ANTIBIOTIC FOR MULTIDRUG-RESISTANT BACTERIA | MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) | 2020-05-21 | — | — | US | disclosed |
| CN-104736000-A | Salty taste enhancer, method for producing same, and salty taste enhancing method | NISSIN FOODS HOLDINGS CO LTD | 2015-06-24 | — | — | CN | disclosed |
| EP-2534138-A1 | 1,2,3-TRIAZOLE-BASED PEPTIDOMIMETIC INTEGRIN INHIBITORS FOR THE DIAGNOSIS AND THERAPY OF TUMORS | Universita' Degli Studi di Firenze (IT) | 2012-12-19 | — | — | EP | disclosed |
| WO-2011098603-A1 | 1,2,3-TRIAZOLE-BASED PEPTIDOMIMETIC INTEGRIN INHIBITORS FOR THE DIAGNOSIS AND THERAPY OF TUMORS | UNIVERSITA' DEGLI STUDI DI FIRENZE (IT) | 2011-08-18 | — | — | WO | disclosed |
| CN-100343260-C | Cephem compounds | FUJISAWA PHARMACEUTICAL CO (JP) | 2007-10-17 | — | — | CN | disclosed |
| EP-1753733-A1 | SMALL MOLECULES FOR TREATMENT OF HYPERCHOLESTEROLEMIA AND RELATED DISEASES | Avanir Pharmaceuticals (US) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005123700-A1 | SMALL MOLECULES FOR TREATMENT OF HYPERCHOLESTEROLEMIA AND RELATED DISEASES | AVANIR PHARMACEUTICALS (US) | 2005-12-29 | — | — | WO | disclosed |
| CN-1708502-A | Cephem compounds | FUJISAWA PHARMACEUTICAL CO (JP) | 2005-12-14 | — | — | CN | disclosed |
| EP-1556389-A1 | CEPHEM COMPOUNDS | Astellas Pharma Inc. (JP) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004039814-A1 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2004-05-13 | — | — | WO | disclosed |
| WO-2002014349-A2 | NON-COVALENT INHIBITORS OF UROKINASE AND BLOOD VESSEL FORMATION | CORVAS INTERNATIONAL, INC. (US) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200155582-A1 | EFFECTIVE AMINOGLYCOSIDE ANTIBIOTIC FOR MULTIDRUG-RESISTANT BACTERIA | ABCC1, ABCB11, SLC11A2 | F2 4752/4885PRSS1 1757/4885PRSS2 1975/4885 |
| US-11135234-B2 | Effective aminoglycoside antibiotic for multidrug-resistant bacteria | ABCC1, ABCB11, SLC11A2 | F2 4752/4885PRSS1 1757/4885PRSS2 1975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.